

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/051,662	01/18/2002	Gustavo C. Rodriguez	31140B	3102
75	90 03/26/2003			
Raymond N. Nimrod			EXAMINER	
Suite 1000 200 South michigan Avenue		GOLDBERG, JEROME D		
Chicago, IL 60			ART UNIT	PAPER NUMBER
			1614	
			DATE MAILED: 03/26/2003	,

Please find below and/or attached an Office communication concerning this application or proceeding.

, i	Application	No.	Applicant(s)				
· ·		illo.					
Office Action Summary	10/051,662		RODRIGUEZ ET AL.				
Office Action Summary	Examiner		Art Unit				
The MAILING DATE of this communication a	Jerome D Go		orrespondence address				
Period for Reply	ppears on the o	570, 57700t William 0.0 0					
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR of after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a recommendation of the period for reply is specified above, the maximum statutory perions are reply within the set or extended period for reply will, by status and patent term adjustment. See 37 CFR 1.704(b). Status	I. 1.136(a). In no event, eply within the statutor od will apply and will ex ute, cause the applica	however, may a reply be tim ry minimum of thirty (30) day expire SIX (6) MONTHS from tion to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
1)⊠ Responsive to communication(s) filed on 15	5 February 2002	<u>2</u> .					
,— ·	This action is no						
3) Since this application is in condition for allo	wance except fo	or formal matters, pr	rosecution as to the merits is				
closed in accordance with the practice under Disposition of Claims		iyle, 1935 C.D. 11, 4	193 O.G. 213.				
4)⊠ Claim(s) <u>35-64</u> is/are pending in the applica							
4a) Of the above claim(s) is/are withdo	rawn from cons	ideration.					
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
	Claim(s) is/are objected to.						
8) Claim(s) 35-64 are subject to restriction and	or election requ	uirement.					
Application Papers	nor						
9) The specification is objected to by the Exami10) The drawing(s) filed on is/are: a) ac		hiected to by the Exa	miner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for fore	eign priority und	er 35 U.S.C. § 119(a	a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the p application from the International * See the attached detailed Office action for a l 	Bureau (PCT R	tule 17.2(a)).					
14)☐ Acknowledgment is made of a claim for dome	estic priority und	der 35 U.S.C. § 119((e) (to a provisional application).				
a) ☐ The translation of the foreign language 15)☐ Acknowledgment is made of a claim for dome							
Attachment(s)							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper Note			ry (PTO-413) Paper No(s) Patent Application (PTO-152)				



Application/Control Number: 10/051,662

Art Unit: 1614

Claims 35-64 are drawn to compositions comprising a vitamin D compound and a hormone product (progestin product).

Applicants state on page 18, lines 7-12 that it "is contemplated that combinations of vitamin D compounds and progestins will exhibit not only additive but synergistic effects in the induction of apoptosis of non-neoplastic ovarian epithelial cells: In this manner the adverse physiological effects of administering larger quantities of Vitamin D compounds and of progestin products can be minimized. "Applicants are, therefore, required to elect a single synergistic combination of one vitamin D compound with one hormone product for examination on the merits.

The several inventions above are independent and distinct, each from the other, as they have acquired a separate status in the art of treating ovarian epithelial cells as a separate subject matter for inventive effect and require independent searches. It is noted that a reference to one synergistic combination of drugs would not be a reference to another synergistic combination of drugs under 35 U.S.C. 103. Further, the claims read on a multitude of synergistic combinations of drugs which would require many field of searches that would be an undue burden on the Examiner. Therefore, restriction for examination purposes is proper.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jerome Goldberg whose telephone number is (703) 308-4606. The examiner can normally be reached on Monday-Thursday 9:00 A.M - 3:00 P.M.



Application/Control Number: 10/051,662

Art Unit: 1614

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-4556 for regular communications and (703) 305-3592 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Goldberg/tgd March 24, 2003

JEROME D. GOLDBERG PRIMARY EXAMINER